Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback